

STELLAR³⁰⁴



Learn More About a Clinical Trial for Metastatic Kidney Cancer

This guide can help you talk with your doctor about joining a clinical trial. The first step is to ask your doctor if you may be eligible to take part in this study.

STELLAR-304 is a clinical trial to check whether a new investigational combination of two medicines, zanzalintinib and nivolumab, will work to treat kidney cancer with papillary, unclassified, and translocation-associated subtypes that has spread to other parts of the body (metastatic cancer). More information about STELLAR-304 can be found at stellarkidneycancerstudy.com or on clinicaltrials.gov by searching for **NCT05678673**. Ask your doctor if you may be eligible.

Questions to Help You Start the Conversation About:

Clinical Trial Participation

- What are my treatment options? Is a clinical trial an option for me?
- What are the potential risks and benefits?
- What if I decide to leave the trial early?
- Will I be able to get other treatment if the medicines in the clinical trial don't work for me?
- How will my safety be monitored during the trial?
- Are translation services offered? Can you share materials in my native language?

Impact on Daily Life

- Is there a clinical trial site near me?
- How long will I be in the trial?
- How often will I have to visit the study site?
- Will I have to stay overnight in a hospital?
- Can I bring a support person/family member to my study visits?
- Will the trial keep me or my family from our normal daily life?

Financial Costs

- Will it cost me anything to be in the study?
- Will the medications be covered by my health insurance?
- Will I be able to continue working if I participate in the trial?

If your doctor is not taking part in STELLAR-304 research, you may want to discuss these questions with a doctor who is.

For more information, please call Exelixis Medical Information at **1-888-393-5494** (toll-free) or **1-303-389-1847**, or email medinfo@exelixis.com.

EXELIXIS IS DEDICATED TO ENSURING THE INCLUSION OF INDIVIDUALS FROM DIVERSE BACKGROUNDS IN OUR CLINICAL TRIALS.

THE COMBINATION OF ZANZALINTINIB AND NIVOLUMAB HAS NOT BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA). THE SAFETY AND EFFECTIVENESS OF THIS STUDY TREATMENT HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.